A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as First Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma

Condition:   Esophageal Squamous Cell Carcinoma (ESCC)
Interventions:   Drug: Platinum (cisplatin or oxaliplatin) + Fluorouracil (5-FU);   Drug: Platinum (cisplatin or oxaliplatin) + capecitabine;   Drug: Platinum (cisplatin or oxaliplatin) + paclitaxel
Sponsor:   BeiGene
Recruiting

http://bit.ly/2EKMZXO